Kinetics of crystal transformation of imatinib mesylate during formulation process: Selection of dry granulation in pharmaceutical process

Takanori Komai,Taichirou Togo,Hiromasa Uchiyama,Kazunori Kadota,Yuichi Tozuka

DOI: https://doi.org/10.1016/j.powtec.2024.119570

IF: 5.64

2024-03-08

Powder Technology

Abstract:The change in crystal form of active pharmaceutical ingredients affects the physicochemical stability and the operability in formulation processes. In generic imatinib mesylate (IMT), the development of manufacturing methods that enable stable production while adhering to patent regulations is required. We developed tablets containing >80% IMT with unstable α-form crystals. The crystal transformation behavior in formulation processes was identified, along with the crystal transition factor in tablets, meaning the crystalline transition of IMT occurred through the existence of water in tablet. Dry granulation was selected by considering the presence of water in the crystal transition of IMT from the unstable α-form to stable β-form. According to the Hancock–Sharp equation, the crystal transition of IMT followed a specific solid-state reaction kinetics. Tablets containing >80% IMT were successfully developed, and crystal transition from α- to β-form was not expected to occur for three years at 25 °C.

engineering, chemical